Newsletter - Issue no. 3

Dear Colleagues and Friends,

I am thrilled to share with you our newest developments achieved in the past months - whether it comes to new collaborations, approvals, research or operational developments, Alpha Tau is rapidly progressing!

In the last several weeks, we have seen tremendous interest from the medical community in our Alpha DaRT treatment. Committees at the most prestigious industry meetings, including the American Societies for Radiation Oncology (ASTRO) and Brachytherapy (ABS), selected our scientists to present their latest results from our preclinical and clinical studies.

I am even more excited to report that Prof. Keisari, the co-inventor of the Alpha DaRT technology, won the Best Oral Presentation Award at this year’s annual ABS meeting for his talk on immunomodulation of the antitumor response induced by Alpha DaRT.

In parallel, leading experts worldwide are now developing a broad array of studies that will investigate the Alpha DaRT from the cellular level to the entire system and across a variety of indications.

Yet all of this would not be possible if it wasn’t for your support! A big thank you to every single one of our team members and collaborators - employees, scientists, investors, patients and caregivers - for your interest, motivation, hard work and your investment into making Alpha DaRT available to cancer patients worldwide.


Uzi Sofer CEO & Chairman


  • Operations

  • Welcome to our new CFO Raphi Levy!

  • Increased production capacity in Israel

  • New larger offices

  • Initial steps towards production and distribution in Asia

  • Regulatory Updates

  • ISO - Getting closer to CE

  • Regulatory Milestones in Canada

  • R&D

  • First clinical trial completed!

  • Japan pivotal trial launched

  • Clinical trial launched for metastatic breast cancer

  • International research collaboration - final steps before initiation

  • New agreements with Israeli Innovation Authority

  • Conferences

  • Prof. Keisari wins Best Oral Presentation Award at ABS Annual Meeting

  • ESTRO Meeting - News and highlights

  • Outstanding presence at TAT11

  • Set a Meeting at Upcoming Conferences

  • American Association for Physics Meeting (AAPM), July 14 - 18, San Antonio, US

  • ICRR (International Congress for Radiation Research), August 25 - 29, Manchester, UK

  • ASTRO Annual Meeting, September 15 - 18, Chicago, US

  • GEC ESTRO Workshop, November 21 - 22, Budapest, Hungary


Welcome to our new CFO Raphi Levy!

We are excited to welcome our new CFO, Raphi Levy. Leveraging his unique experience and long-standing international relationships, Raphi will contribute to driving business growth and to securing long-term fundraising that will support our extensive R&D strategy. "I am thrilled to join Alpha Tau and take part in a revolutionary new therapy for cancer patients. I look forward to being part of this outstanding team and to helping drive the company's strategy and commercial relationships in the future," commented Raphi. Raphi has spent the past 13 years working in the Investment Banking Division at the leading financial institution Goldman Sachs in New York and Tel Aviv, most recently serving as Executive Director in charge of healthcare banking in Israel.

Read more

Increased production capacity in Israel

After months of detailed planning, our engineering and production teams have successfully upgraded our production facility in Israel. By implementing new manufacturing technologies, the facility will now allow us to increase the capacity dramatically, by more than 4x. This upgrade will also enable the supply of seeds for clinical studies to remote sites in the Far East and Europe.

New larger offices

As our team keeps growing we have now expanded into new office space at Campus Broshim next to Tel Aviv University. It is only a matter of time until even further space will be needed for the continuous flow of new recruits! A big thanks to Eliran Ron and Or Nahum for the amazing space design and construction!

Initial steps towards production and distribution in Asia

After a productive visit in Japan, our team has started first preparations towards commercialization in Asia, with Japan in focus. We are currently in the first stages of planning and building a Japanese manufacturing facility. In parallel, we are in initial discussions with pharmaceutical and medical device companies who might help distribute our products in Japan.

Regulatory Updates